Recombinant Influenza Vaccination in U.S. Nursing Homes
Study Description
“Recombinant Influenza Vaccination in U.S. Nursing Homes”
Based on recent evidence on the mutation of the A/H3N2 strain in egg-grown vaccine, the investigators will study the quadrivalent recombinant influenza vaccine (RIV4, Flublok) compared to the standard dose quadrivalent vaccine (IV4) in a cohort of long-stay NH residents with a primary endpoint of all-cause respiratory-related hospitalization.
Location
Methods
No pharmaceutical medication involved
Patients and healthy individuals accepted
Biological - Recombinant Influenza Vaccine
Nursing home residents and staff 18 years and older are allocated to receive quadrivalent recombinant influenza vaccine.
Biological - Standard Dose Quadrivalent Influenza Vaccine
Nursing home residents and staff 18 years and older are allocated to receive standard dose quadrivalent influenza vaccine
Additional Information
Official Study Title
Comparative Effectiveness of Recombinant Versus Standard Dose Quadrivalent Influenza Vaccine in U.S. Nursing Homes
Clinical Trial ID
NCT03965195
ParticipAid ID
dJ6xKd
